The United States Food and Drug Administration (FDA) has approved the world’s first treatment for the deadly Ebola virus. The treatment, Inmazeb, is a combination of three genetically-engineered antibodies. The company Regeneron Pharmaceuticals developed it to treat both young and old patients with the virus version called Zaire Ebola. It is the deadliest kind of Ebola known to infect humans. Zaire Ebola usually kills 60 to 90 percent of patients. FDA officials announced the approval of Inmazeb on Wednesday. The Zaire Ebola virus can spread easily through direct contact with body fluids of infected people or animals. Signs of the disease include increased body temperature, pain, stomach sickness, kidney and liver damage, and bleeding. People who provide care to infected individuals are at highest risk of contracting the virus.
